Injection instead of lab: new CAR-T therapy could transform blood cancer care
NCT ID NCT07362602
First seen Jan 31, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This early-phase study tests a new type of CAR-T therapy that is given as an injection, instead of the usual process of removing and modifying cells in a lab. It targets a protein called CD20 found on certain blood cancer cells. The goal is to see if this approach is safe and effective for people with B-cell lymphomas or leukemias that have not responded to other treatments. About 47 adults aged 18 to 70 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.